Posted by Michael Wonder on 18 Jul 2025
Aldeyra Therapeutics announces FDA acceptance for review of reproxalap new drug application for the treatment of dry eye disease
17 July 2025 - PDUFA target action date 16 December 2025.
Aldeyra Therapeutics today announced that the US FDA has accepted for review the resubmitted new drug application for topical ocular reproxalap, a first in class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease.
